Prediction of the pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index;Pradiktion der pharmakologischen wirkung von octreotid bei akromegalie mittels 111In-pentetreotid-szintigraphie und berechnung eines hypophysaren uptake-index

NuklearMedizin

Volumn 36, Issue 4, 1997, Pages 117-124

  Gorges R ^a,c   Cordes, U ^b   Engelbach, M ^a   Bartelt, K M ^b   Haberern, G ^a   Hey, O ^a   Beyer, J ^a   Bockisch, A ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Arbeitsgemeinschaft N   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

111 In pentetreotide scintigraphy; Acromegaly; Octreotide; Pituitary adenomas; Somatostatin receptors

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DIAGNOSTIC AGENT; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; INDIUM; OCTREOTIDE; PENTETREOTIDE; SOMATOSTATIN;

ACROMEGALY; ARTICLE; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HYPOPHYSIS ADENOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADENOMA; ADULT; AGED; FEMALE; HYPOPHYSIS; HYPOPHYSIS TUMOR; MALE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; PROGNOSIS; SCINTISCANNING; SECRETION; TISSUE DISTRIBUTION;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INDIUM RADIOISOTOPES; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY GLAND; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SOMATOSTATIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0031158248     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629870     Document Type: Article

References (34)

1. Bajc M, Palmer J, Ohlsson T, Edenbrandt L. Distribution and dosimetry of 111-In-DT-PA-D-Phe-octreotide in man assessed by whole body scintigraphy. Acta Radiologica 1994; 35: 53-7.
2. Becker W, Schrell U Lohner W et al. In-111-octreotide-SPECT in patients with brain and pituitary tumors. J Nucl Med 1993; 34: 37P (Abstract 140).
3. Duet M, Mundler O, Ajzenberg C et al. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index. Eur J Nucl Med 1994; 21: 647-50.
4. Ezzat S, Horvath E, Harris HG, Kovacs K. Morphologic effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79: 113-8.
5. Ezzat S, Snyder PJ, Young WF et al. Octreotide treatment of acromegaly - a randomized, multicenter study. Ann Intern Med 1992; 117: 711-8.
6. Fahlbusch R, Giovanelli M, Buchfelder M, Losa M et al. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. J Endocrinol Invest 1993; 16: 449-60.
7. Flogstad AK, Halse J, Grass P et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994; 79: 461-5.
8. Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol 1994; 41: 103-8.
9. Gorges R, Eißner D, Kahaly G et al. Darstellung von Metastasen eines Schilddrüsenkarzinoms mittels 111-In-Pentetreotide-Szintigraphie. Nuklearmedizin 1995; 34: 165-9.
10. Gupta P, Waxman A, Nguyen K et al. Quantitative evaluation of Indium-111 (In-111) octreotide pituitary activity: comparison in patients with and without pituitary tumors. J Nucl Med 1995; 36: 15P-16P (Abstract 53).
11. Haberern G, Görges R, Bockisch A. Quantifizierung eines pathologischen Somatostatin-Rezeptorstatus im In-111-Pentetreotide-SPECT bei Hypophysentumoren. Nuklear-medizin 1995; 34: A 159 (Abstract P 115).
12. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
13. Lamberts SWJ, de Herder WW, Kwekkeboom DJ et al. Current tools in the diagnosis of pituitary tumours. Acta Endocrinologica 1993; 129 (Suppl. 1): 6-12.
14. Lamberts SWJ, Hofland LJ, de Herder WW. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Fontiers Neuroendocrinol 1993; 14: 27-55.
15. Lamberts SWJ, Uitterlinden P, Schuijff PC, Klijn JGM. Therapy of acromegaly with Sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical cure. Clin Endocrinol 1988; 29: 411-20.
16. Lastoria S, Colao A, Vergara E et al. Indium-111 octreotide uptake levels in pituitary adenomas to predict the responsiveness to chronic octreotide treatment. J Nucl Med 1994; 35: 166P (Abstract 668).
17. van Liessum PA, Pieters GF, Smals AG et al. Single-dose response study of the somatostatin analogue octreotide in acromegaly. Acta Endocrinologica 1989; 121: 714-20.
18. Lucs-Morante T, Garcia-Uria J, Estrada J et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 1994; 81: 10-4.
19. Maini CL, Sciuto R. Tofani A et al. Somatostatin receptor imaging in CNS tumors using 111-In-octreotide. Nucl Med Commun 1995; 16: 756-66.
20. Mehltretter G, Heinz S, Schopohl J et al. Long-term treatment with SMS 201-995 in resistant acromegaly: effectiveness of high doses and continuous subcutaneous infusion. Klin Wochenschr 1991; 69: 83-90.
21. Messerschmidt D, Fett U, Reichel M et al. Somatostatin receptor scintigraphy and pituitary tumor volume, hormone concentration and response to octreotide scintigraphy. Exp Clin Endocrinol 1995; 103 (Suppl. 1): 56 (Abstract P56).
22. Miller GM, Alexander JM, Bikkal HA et al. Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 1995; 80: 1386-92.
23. Patel YC, Greenwood MT, Panetta R et al. The somatostatin receptor family. Life Sci 1995; 57: 1249-65.
24. Pinkert J, Oehme L, Franke WG, Gerbert B. Pituitary uptake index for semiquantitative determination of somatostatin receptors in adenomas. Eur J Nucl Med 1994; 21: 779 (Abstract 220).
25. Plöckinger U, Reichel M, Fett U et al. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79: 1416-23.
26. Possa M, Sara R, Ruffini L et al. 111-In-pentetreotide scintigraphy in pituitary adenomas. Eur J Nucl Med 1994; 21: 764 (Abstract 159).
27. Reubi JC, Landoldt AM, The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 1989; 68: 844-50.
28. Schmidt K, Althoff PH, Harris A et al. Langzeitbehandlung der Akromegalie mit dem Somatostatinanalogon Octreotid (Sandostatin). Zur prädiktiven Bedeutung von Akuttests. Medizinische Klinik 1990; 85: 700-6.
29. Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinologica 1993; 129 (Suppl. 1): 18-20.
30. Timsit J, Chanson P, Harris AG et al. Short-term continuous infusion of octreotide in acromegaly. Pharmacokinetics and prediction of the response to long-term treatment. Horm Metab Res 1991; 23: 48-9.
31. Ur E, Mather SJ, Bomanji J et al. Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol 1992; 36: 147-50.
32. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide - results of the international multicenter acromegaly study group. Arch Intern Med 1991; 151: 1573-8.
33. Verhoeff NPLG, Meylaerts SAG, Miedema AR et al. Somatostatin receptor imaging in the pituitary using (In-111-DTPA)-octreotide and high resolution brain SPECT. J Nucl Med 1993; 34: 41P-42P (Abstract 159).
34. Wagenaar AH, Harris AG, van der Lely AJ, Lamberts SW. Dynamics of the acute effects of octreotide. bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinologica 1991; 125: 637-42.